A randomized phase II trial of outpatient immunotherapy with rituximab and aldesleukin (IL-2) vs. rituximab alone for CD20 positive aggressive non-Hodgkin's lymphoma following high dose therapy with autologous PBSC [peripheral blood stem cell] rescue
Latest Information Update: 07 Apr 2022
At a glance
- Drugs Aldesleukin (Primary) ; Rituximab (Primary)
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- 29 Nov 2005 New trial record.